Pluristem Therapeutics Inc. (NASDAQ:
PSTI; DAX: PJT)
is a bio-therapeutics
company dedicated to the commercialization of unrelated donor-patient (allogeneic)
cell therapy products for the treatment of several severe degenerative, ischemic
and autoimmune disorders. The Company is developing a pipeline of products
derived from human placenta, a non-controversial, non-embryonic, adult stem cell
source. The (PLacental eXpanded) cell products are stored off-the-shelf,
ready-to-use, and require no histocompatibility matching.
These placental adherent stromal cells (ASCs) are expanded in the Company's
proprietary PluriXTM 3D bioreactor system, which provides a 3D microenvironment
that enables large-scale growth of these cells without the need for supplemental
growth factors or other exogenous materials. PLX cells are immune privileged,
possess immunomodulatory properties, and are expanded in vitro without showing
signs of phenotypic or karyotypic changes. Pluristem believes that the PLX
cells’ mechanism of action may be related to the secretion of cytokines and/or
other potent immune modulators.
Pluristem's first product, PLX-PAD (for the treatment of Peripheral Artery
Disease), received from the Food and Drug Administration (FDA) and the Paul
Ehrlich Institute (PEI), the German competent authority in the European Union,
clearance to begin a “First-In-Human” placental-derived mesenchymal-like stromal
cell clinical trial.
Pluristem has offices in the USA with research and manufacturing facilities in
Israel.